- Home
- MAGH vs MDXH Comparison
MAGH vs MDXH Comparison
Compare MAGH & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MAGH | MDXH |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | Singapore | Belgium |
| Employees | N/A | 312 |
| Industry | Engineering & Construction | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 225.4M | 167.8M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MAGH | MDXH |
|---|---|---|
| Price | $6.85 | $3.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | ★ 1.2M | 177.1K |
| Earning Date | 12-23-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | $11,752,129.00 | ★ $103,069,000.00 |
| Revenue This Year | N/A | $23.34 |
| Revenue Next Year | N/A | $22.98 |
| P/E Ratio | $7,194.11 | ★ N/A |
| Revenue Growth | N/A | ★ 21.68 |
| 52 Week Low | $0.99 | $1.35 |
| 52 Week High | $6.94 | $5.33 |
Technical Indicators
Market Signals| Indicator | MAGH | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 34.99 |
| Support Level | N/A | $3.31 |
| Resistance Level | N/A | $3.74 |
| Average True Range (ATR) | 0.00 | 0.18 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 8.65 |
Price Performance
Historical ComparisonAbout MAGH Magnitude International Ltd Ordinary Shares
Magnitude International Ltd is providing electrical installation services to customers in both the private and public sectors in Singapore. It includes the planning, design, material selection, installation, testing, commissioning and certification of the electrical equipment/systems to be installed. The Group's revenue is derived from Singapore.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.